Drug Store News - Janssen Pharmaceutica - Risperdal Consta approved - Brief Article
The FDA last month approved Risperdal Consta (risperidone long-acting injection) for treating schizophrenia. It is the first long-acting, atypical antipsychotic the FDA has approved, reported Janssen Pharmaceutica, who is marketing the product.
Related Results
Antipsychotic treatment: when to measure prolactin.(Adult Psychiatry)
Patent challenge.(BARR Laboratories Inc., Janssen Pharmaceutica Products L.P….
Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Confe…
CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Confe…
WALL STREET CHOICE J&J SHARES REFLECT SLOWING PHARMA GROWTH
The treatment uses advanced technology to deliver and maintain therapeutic medication levels in the body through one injection every two weeks.
COPYRIGHT 2003 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2008 Gale, Cengage Learning
